Concord manufactures and supplies immunosuppressant range of finished products to the USA market. Our partnership driven business model has helped us leverage our strengths in product development and manufacturing while our partners have utilized their strengths in marketing the products.

We have successfully launched ANDA's in the USA and have a strong pipeline of products, which we intend to commercialize in the coming years to ensure robust growth going forward.

We are also exploring opportunities to collaborate with Companies across other geographies through various business models such as out-licensing, co-marketing etc. in order to provide high quality and bio-equivalent finished products to patients.

Sr. No Product Name ANDA# Approval Date Pack Style
1 Mycophenolate Mofetil Capsules, USP 250mg 210181 8-Jan-19 100 counts in HDPE bottles
500 counts in HDPE bottles
2 Mycophenolic Acid DR Tablets USP, 180 mg and 360 mg 211173 13-Dec-19 120 counts in HDPE bottles
3 Mycophenolate Mofetil Tablets, USP 500mg 212087 31-Jul-2020 100 counts in HDPE bottles
500 counts in HDPE bottles
4 Tacrolimus Capsules USP, 0.5, 1 and 5 mg 213112 10-Nov-2020 100 counts in HDPE bottles